Alexander Denner
Director/Board Member at IRONWOOD PHARMACEUTICALS, INC.
Net worth: 4 M $ as of 2024-03-30
Alexander Denner active positions
Companies | Position | Start | End |
---|---|---|---|
IRONWOOD PHARMACEUTICALS, INC. | Director/Board Member | 2020-11-08 | - |
Independent Dir/Board Member | 2020-11-08 | - | |
Biogen GmbH
Biogen GmbH Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen GmbH is a pioneer in the field of neuroscience since 1978. The private company is based in Ismaning, Germany. Biogen focuses on research in therapeutic areas with a strong emphasis on difficult-to-treat diseases. The German company was founded in 1978 by Charles Weissman, Kenneth Murray, Heinz Schaller, Phillip Sharp, Walter Gilbert. The CEO is Michel Pericles Vounatsos. | Director/Board Member | 2008-12-31 | - |
Sarissa Capital Management LP
Sarissa Capital Management LP Investment ManagersFinance Sarissa Capital Management LP (Sarissa) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Greenwich, Connecticut. The firm was founded in 2012 by Alexander Denner and Mayuran Sriskandarajah. Sarissa provides investment advisory services to pooled investment vehicles operating as private investment funds. | Chief Executive Officer | 2011-12-31 | - |
Chief Investment Officer | 2011-12-31 | - | |
Founder | 2011-12-31 | - | |
Portfolio Manager-Equities | 2011-12-31 | - | |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | Director/Board Member | 2021-09-07 | - |
Independent Dir/Board Member | 2021-09-07 | - |
Career history of Alexander Denner
Former positions of Alexander Denner
Companies | Position | Start | End |
---|---|---|---|
BIOGEN INC. | Director/Board Member | 2009-06-03 | 2023-06-25 |
Independent Dir/Board Member | 2009-06-03 | 2023-06-25 | |
SARISSA CAPITAL ACQUISITION CORP. | Chief Executive Officer | 2020-09-23 | 2022-11-30 |
Chairman | 2020-09-23 | 2022-11-30 | |
THE MEDICINES COMPANY | Chairman | 2018-03-31 | 2020-03-31 |
BIOVERATIV INC | Director/Board Member | 2017-01-09 | 2018-03-07 |
ARIAD PHARMACEUTICALS, INC. | Director/Board Member | 2014-02-19 | 2016-01-07 |
Chairman | 2016-01-07 | 2017-02-15 | |
Independent Dir/Board Member | 2014-02-19 | 2017-02-15 | |
░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░ ░░░░░░ ░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | ░░░░░░░░░░ |
░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | ░░░░░░░░░░ |
░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░ ░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ ░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░ ░░░░ ░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Training of Alexander Denner
Massachusetts Institute of Technology | Undergraduate Degree |
Yale University | Doctorate Degree |
Statistics
International
United States | 24 |
Cayman Islands | 2 |
Germany | 2 |
Operational
Director/Board Member | 16 |
Independent Dir/Board Member | 6 |
Chairman | 4 |
Sectoral
Health Technology | 15 |
Finance | 7 |
Miscellaneous | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
ENZON PHARMACEUTICALS, INC. | Health Technology |
BIOGEN INC. | Health Technology |
IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
Private companies | 20 |
---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Forest Laboratories, Inc.
Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
VIVUS, Inc.
VIVUS, Inc. Pharmaceuticals: MajorHealth Technology VIVUS, Inc. engaged in the development and commercialization of novel therapeutic products. The firm’s products were indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and it was headquartered in Campbell, CA. | Health Technology |
Viking Global Investors LP
Viking Global Investors LP Investment ManagersFinance Viking Global Investors LP (VGI) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Stamford, Connecticut. The firm was founded by O. Andreas Halvorsen and David Ott in 1999. VGI provides investment advice to various private investment funds. Investors in the funds include charitable foundations, endowments, pension plans, sovereign entities, funds-of-funds, investment companies, trusts and individuals. | Finance |
The Medicines Co.
The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Morgan Stanley Investment Management, Inc.
Morgan Stanley Investment Management, Inc. Investment ManagersFinance Morgan Stanley Investment Management, Inc. (MSIM) is an investment management firm headquartered in New York City. The firm was founded in 1975 and is a subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately held by Morgan Stanley (NYSE: MS). MSIM provides discretionary and non-discretionary investment management services and products to institutional clients and individual investors. The firm also advises clients as to the appropriate allocation of assets among multiple separate accounts and/or investment companies or other pooled vehicles that the firm advises. | Finance |
Icahn Partners LP
Icahn Partners LP Investment Trusts/Mutual FundsMiscellaneous Icahn Partners LP is engaged in providing investment services. The company is located in New York city, NY. | Miscellaneous |
Icahn Partners Master Fund LP | Miscellaneous |
Icahn Capital LP | Miscellaneous |
Sarissa Capital Management LP
Sarissa Capital Management LP Investment ManagersFinance Sarissa Capital Management LP (Sarissa) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Greenwich, Connecticut. The firm was founded in 2012 by Alexander Denner and Mayuran Sriskandarajah. Sarissa provides investment advisory services to pooled investment vehicles operating as private investment funds. | Finance |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | Finance |
HyperMed, Inc.
HyperMed, Inc. Medical DistributorsDistribution Services HyperMed, Inc. develops medical imaging devices. The firm provides its services to the vascular surgeons, vascular laboratories, foot and ankle surgeons, podiatrists, research organizations, and educational institutions. The company was founded in 1997 and is headquartered in Burlington, MA. | Distribution Services |
Bioverativ, Inc.
Bioverativ, Inc. BiotechnologyHealth Technology Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA. | Health Technology |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | Health Technology |
Sarissa Capital Acquisition Corp.
Sarissa Capital Acquisition Corp. Financial ConglomeratesFinance Sarissa Capital Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination with one or more businesses. The company was founded on August 12, 2020 and is headquartered in Greenwich, CT. | Finance |
Biogen GmbH
Biogen GmbH Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen GmbH is a pioneer in the field of neuroscience since 1978. The private company is based in Ismaning, Germany. Biogen focuses on research in therapeutic areas with a strong emphasis on difficult-to-treat diseases. The German company was founded in 1978 by Charles Weissman, Kenneth Murray, Heinz Schaller, Phillip Sharp, Walter Gilbert. The CEO is Michel Pericles Vounatsos. | Health Technology |
- Stock Market
- Insiders
- Alexander Denner
- Experience